EGFR and lung adenocarcinoma: This study applied the latest RWD to assess the relative survival rate and time to treatment failure (TTF) of gefitinib, erlotinib, and afatinib in first-line therapy for patients with advanced lung adenocarcinoma with EGFR mutation, and propensity score (PS) method was performed to adjust the estimated HR.